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ABSTRACT
Objectives To determine the prevalence of autonomic 
dysfunction (dysautonomia) among patients with primary 
Sjögren’s syndrome (PSS) and the relationships between 
dysautonomia and other clinical features of PSS.
Methods Multicentre, prospective, cross-sectional 
study of a UK cohort of 317 patients with clinically 
well-characterised PSS. Symptoms of autonomic 
dysfunction were assessed using a validated instrument, 
the Composite Autonomic Symptom Scale (COMPASS). 
The data were compared with an age- and sex-matched 
cohort of 317 community controls. The relationships 
between symptoms of dysautonomia and various clinical 
features of PSS were analysed using regression analysis.
Results COMPASS scores were signifi cantly higher 
in patients with PSS than in age- and sex-matched 
community controls (median (IQR) 35.5 (20.9–46.0) vs 
14.8 (4.4–30.2), p<0.0001). Nearly 55% of patients 
(vs 20% of community controls, p<0.0001) had a 
COMPASS score >32.5, a cut-off value indicative of 
autonomic dysfunction. Furthermore, the COMPASS total 
score correlated independently with EULAR Sjögren’s 
Syndrome Patient Reported Index (a composite measure 
of the overall burden of symptoms experienced by 
patients with PSS) (β=0.38, p<0.001) and disease 
activity measured using the EULAR Sjögren’s Syndrome 
Disease Activity Index (β=0.13, p<0.009).
Conclusions Autonomic symptoms are common among 
patients with PSS and may contribute to the overall 
burden of symptoms and link with systemic disease 
activity.
INTRODUCTION
Primary Sjögren’s syndrome (PSS) affects 0.05–
0.5% of the adult population depending on selec-
tion bias and the classiﬁ cation criteria used.1 It is 
estimated that ~70% of patients with PSS complain 
of signiﬁ cant fatigue, with many stating it as the 
most disabling symptom of the disease.2 We and 
others have reported several biological associations 
of fatigue in chronic and autoimmune diseases, 
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with dysfunction of the autonomic nervous 
system being one of the most notable biological 
factors.3–5
Several studies have demonstrated an association 
between autonomic dysfunction (dysautonomia) 
and PSS,6–11 but conﬂ icting data have also been 
reported.12–14 However, the relationship between 
autonomic dysfunction and fatigue has been exam-
ined in just two studies with 27 patients each.6 9
Interestingly, data from both of these studies sug-
gest a link between autonomic dysfunction and 
fatigue. However, the predictors of dysautonomia 
have not been fully investigated.
In this study, we determined the prevalence of 
autonomic symptoms in a large, multicentre cohort 
of patients with clinically well-characterised PSS 
in the UK using a well-validated comprehensive 
autonomic symptom-assessment tool. In addition, 
we explored the relationship between symptoms 
of autonomic dysfunction and disease activity, 
patient-reported outcome measures, as well as 
other potentially relevant clinical and laboratory 
variables.
MATERIALS AND METHODS
Patient groups
All patients with PSS in this study are partici-
pants of the UK Primary Sjögren’s Syndrome 
Registry (UKPSSR, www.sjogrensregistry.org).15
The UKPSSR is an on-going cohort of patients with 
PSS funded by the Medical Research Council, UK, 
which aims to facilitate research and clinical trials.
All participants fulﬁ l the American European 
Consensus Group (AECG) classiﬁ cation criteria.16
Informed consent was obtained from all patients 
according to the principles of the Helsinki 
Declaration. All clinical and laboratory data were 
collected prospectively at the time of recruitment 
as previously described.15 Embedded within the 
design of the UKPSSR are several sub-studies aim-
ing to address different clinical questions, one of 
which is the prevalence of autonomic dysfunction 
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using the Composite Autonomic Symptom Scale (COMPASS).17 
Participation in this sub-study is optional. At the time of analy-
sis, 474 patients had been recruited to the UKPSSR, of which 396 
(83.5%) participated in the COMPASS assessment. Complete 
datasets for COMPASS were available for 317 patients. Only 
those with complete datasets for COMPASS were subjected to a 
full analysis because the COMPASS total score cannot be accu-
rately determined with incomplete data.
Each PSS participant with complete COMPASS data was 
matched case by case by age (within 2 years) and sex from an 
existing community control cohort of 596 subjects who had 
completed COMPASS assessments established by one of the 
investigators (JLN).18 19
Assessment of autonomic function 
Composite Autonomic Symptom Scale (COMPASS)
The severity of autonomic symptoms was assessed using 
COMPASS,17 which consists of 73 questions grouped into 
domains describing speciﬁ c autonomic nervous system symp-
toms. Each domain is scored on the basis of the presence, sever-
ity, distribution, frequency and progression of symptoms. The 
10 domains are: orthostatic intolerance, vasomotor, secretomo-
tor, gastroparesis, autonomic diarrhoea, constipation, bladder, 
pupil and focusing, sleep disorder and syncope. COMPASS also 
includes an optional male erectile dysfunction domain, which 
was not included in this study because PSS predominantly 
affects females. The individual domain scores are then weighted 
according to clinical relevance as described in the original 
derivation and validation of the questionnaire.17 The sum of 
the individual scores provides an indicator of overall symp-
tom burden (COMPASS total score). In all domains, a higher 
score indicates increased severity of the autonomic symptom. 
Two domains (‘understatement’ and ‘overstatement’ scales) are 
incorporated into the assessment tool to detect over- or under-
reporting of symptoms between individuals and are scored 
independently.
Assessment of other clinical features of PSS
The following data are collected for all UKPSSR subjects 
regardless of their participation in the COMPASS assessments: 
EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI),20 
EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI)21 
(measurement of the overall burden of symptoms), EULAR 
Sicca Scale21 (measurement of overall severity of dryness), 
Proﬁ le of Fatigue (Pro-F)22–24 (measurement of fatigue), Epworth 
Sleepiness Scale (ESS)25 (measurement of daytime sleepiness), 
Hospital Anxiety and Depression Scale (HAD)26 (assessment 
of anxiety and depression), EuroQol-5 Dimension (EQ-5D)27 
(www.euroqol.org) (measurement of health-related quality of 
life). Further details on these instruments are provided in online 
supplementary ﬁ le 1.
Autoantibodies
Autoantibodies against Ro (SSA) or La (SSB) antigens were meas-
ured in a single laboratory using Euroassay anti-ENA Proﬁ le Plus 
according to manufacturer’s protocol (Euroimmun AG, Lubeck, 
Germany).
Ethics approval
Ethics approval was granted by the North West Research ethics 
committee for the establishment of the UKPSSR and analysis of 
the data and samples.
Statistical analysis
All data were analysed using GraphPad or SPSS software. Not 
all patients in the UKPSSR cohort completed the COMPASS 
questionnaire. Given the large number of variables, differences 
between the three groups were ﬁ rst tested using multivariate 
analysis of variance. If Wilks’ lambda was statistically signiﬁ -
cant (p<0.05), univariate analyses of variance were performed 
to identify which variables contributed to the difference. 
Where these were signiﬁ cant (p<0.05), comparisons were made 
between the COMPASS group and the incomplete-COMPASS 
and non-COMPASS groups. Raw p values unadjusted for 
multiplicity are reported throughout, permitting the application 
of preferred adjustments.
PSS and control groups were compared using Wilcoxon 
matched pairs test (comparison of medians) or Fisher’s exact 
test (comparison of percentages). Pearson’s and Spearman’s tests 
were used for univariate correlation analysis for non-parametric 
and parametric data, respectively. To identify independent pre-
dictors for autonomic symptoms, multivariate stepwise regres-
sion analysis was performed using COMPASS total score as the 
dependent variable, and stepwise logistic regression analysis 
was performed using the COMPASS total score of 32.5 as cut-
off value for the presence or absence of dysautonomia.3
RESULTS
Patient characteristics
The median age of the group of 317 (298 female, 19 male) 
participants with PSS (95.6% Caucasian) who had complete 
datasets on COMPASS was 59.9 years (IQR 49.5–67.1), with 
median disease duration of 6.1 years (IQR 2.5–11.9). Disease 
duration was calculated as time from diagnosis using the AECG 
criteria. Most of these patients (267; 84.2%) had autoantibod-
ies against Ro (SSA) and/or La (SSB). The median (IQR) age of 
the community control group was 60.0 years (49.5–67.0). To 
determine whether those completing the COMPASS (‘complete-
COMPASS’ group) differed clinically from those with incomplete 
COMPASS (‘incomplete-COMPASS’ group) or no COMPASS 
datasets (‘non-COMPASS’ group), multivariate analysis of 
variance was performed, which revealed signiﬁ cant differ-
ences between the three groups (p=0.002). Univariate analyses 
conﬁ rmed several signiﬁ cant differences, in particular age, 
physical fatigue and ESSPRI scores (p<0.01), with the complete-
COMPASS group being younger, with lower levels of fatigue 
and ESSPRI scores (online supplementary table S1(a)–(c)). Box 
plots of the age, physical fatigue and ESSPRI of the three groups 
are shown in ﬁ gure 1.
Symptoms of autonomic dysfunction
The COMPASS domain and total scores for the patients with 
PSS and community controls are shown in ﬁ gure 2 and table 1.
The median (IQR) COMPASS total score for the subjects with 
PSS was 2.4-fold higher (PSS vs control: 35.5 (20.9–46.0) vs 
14.8 (4.4–30.2), p<0.0001). Using the COMPASS total score of 
>32.5 as the diagnostic criterion for autonomic dysfunction,3 we 
found that 173 of the 317 (54.6%) patients with PSS compared 
with 20% of the community controls had evidence of auto-
nomic dysfunction (p<0.0001). Of the 10 COMPASS domains, 
signiﬁ cantly higher scores were observed among the PSS group 
than among the controls in seven domains. The domain scores 
for autonomic diarrhoea, constipation and syncope were com-
parable between patients with PSS and controls, suggesting that 
patients with PSS experience many, but not all, symptoms that 
are related to autonomic dysfunction.
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Two of the ten questions in the secretomotor domain assess 
symptoms of oral and ocular dryness, which are also key symp-
toms of PSS. Therefore, patients with PSS may give positive 
responses to these questions regardless of the underlying aetiol-
ogy of their sicca symptoms. To investigate how these ques-
tions might bias the secretomotor domain and COMPASS total 
scores, we compared the secretomotor domain and COMPASS 
total scores between patients with PSS and controls by scoring 
these two items as ‘negative’. With this approach, the median 
(IQR) secretomotor scores were 1.5 (1.5–4.5) and 1.5 (0–3.0) for 
patients with PSS and controls, respectively (p<0.0001), and the 
median (IQR) COMPASS total score was 29.2 (16.2–40.4) for 
Figure 1 Box plots showing the median, interquartile ranges, extreme ranges and extreme values for (A) age, (B) physical fatigue and (C) ESSPRI of 
the complete-COMPASS group and the remaining groups of the cohort. COMPASS, Composite Autonomic Symptom Scale; ESSPRI, EULAR Sjögren’s 
Syndrome Patient Reported Index.
Table 1 Data on COMPASS total and individual domain scores of 
patients with PSS and community controls
COMPASS domain 
COMPASS score
PSS vs 
controls* PSS Controls
Orthostatic intolerance 12.5 (2.5–17.5) 0.0 (0.0–12.5) <0.0001
Vasomotor 0.0 (0.0–5.0) 0.0 (0.0–0.0) <0.0001
Secretomotor 7.5 (7.5–9.0) 1.5 (0.0–4.5) <0.0001
Gastroparesis 0.0 (0.0–1.7) 0.0 (0.0–0.0) 0.0001
Autonomic diarrhoea 0.0 (0.0–8.0) 2.0 (0.0–8.0) 0.21
Constipation 1.5 (0.0–3.0) 1.5 (0.0–3.0) 0.25
Bladder control 2.0 (0.0–4.0) 2.0 (0.0–2.0) 0.0002
Pupil and focusing 2.0 (1.0–3.0) 0.5 (0.0–1.5) <0.0001
Sleep disorders 1.5 (0.0–2.3) 0.0 (0.0–1.5) <0.0001
Syncope 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.35
COMPASS total 35.5 (20.9–46.0) 14.8 (4.4–30.2) <0.0001
Understatement 1.7 (0.0–3.3) 6.0 (2.0–8.0) <0.0001
Overstatement 0.0 (0.0–1.8) 0.0 (0.0–7.0) <0.0001
Values are median (IQR).
*Wilcoxon matched pairs test.
COMPASS, Composite Autonomic Symptom Scale; PSS, primary Sjögren’s syndrome.
Figure 2 The COMPASS total scores of the patients with primary 
Sjögren’s syndrome (PSS) and the age- and sex-matched community 
controls. Each dot represents the individual COMPASS total score of the 
groups. COMPASS, Composite Autonomic Symptom Scale.
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patients with PSS and 14.8 (4.4–29.6) for controls (p<0.0001). 
In addition, we compared the COMPASS total scores between 
patients with PSS and controls without the entire secreto motor 
domain. With this approach, the median (IQR) COMPASS total 
scores were 26.6 (13.7–36.7) and 13 (4.3–26.3), respectively, for 
patients with PSS and controls (p<0.0001). These additional 
analyses suggest that the difference in the COMPASS total score 
between patients with PSS and controls cannot be explained by 
potential bias in the secretomotor domain alone.
Relationship between autonomic symptoms and clinical 
features of PSS
To explore the relationship between autonomic symptoms and 
clinical features of PSS, we performed univariate correlation anal-
ysis between COMPASS total score and a range of prespeciﬁ ed 
variables including demographics (age, sex), measures of disease 
activity and severity (disease duration, ESSDAI, erythrocyte 
sedimentation rate, C-reactive protein, physician’s assessment 
of disease damage, autoantibody status), patient reported out-
comes (ESSPRI, dryness (EULAR Sicca Score, overall dryness), 
pain, fatigue (physical fatigue, mental fatigue, overall fatigue), 
anxiety, depression, daytime somnolence, health-related quality 
of life) and other potentially relevant factors (systolic and diasto-
lic blood pressure). These variables were chosen on the basis of 
potential biological links and data from previous studies.
There was no correlation between COMPASS total score and 
age, disease duration, blood pressure, erythrocyte sedimentation 
rate or C-reactive protein. The median COMPASS total scores 
were not signiﬁ cantly different between patients with or with-
out autoantibodies against Ro/La or between female and male 
patients (data not shown). There was a signiﬁ cant correlation 
between the COMPASS total score and ESSDAI, but not with 
the physician-assessed severity of end-organ damage measured 
using a Likert scale. Total autonomic symptom burden was asso-
ciated most strongly with ESSPRI, followed by fatigue and pain. 
The presence of autonomic symptoms was also associated with 
dryness, daytime sleepiness, anxiety, depression and reduced 
quality of life (online supplementary table S2).
To identify multivariate predictors of COMPASS total scores, 
stepwise multiple regression analysis was used. Gender and 
anti-Ro/La status were entered as dummy variables, and good-
ness of ﬁ t was assessed through residual analysis. Stepwise 
multiple regression identiﬁ ed three important predictors of 
COMPASS total scores: ESSPRI (β=0.38, p<0.001), anxiety score 
(HAD-A) (β=0.23, p<0.001) and ESSDAI (β=0.13, p<0.009). 
As these scores increased, COMPASS total scores increased. 
These three predictors accounted for 41% of the variability in 
COMPASS scores. Mental fatigue also independently predicted 
COMPASS total score, but the effect was small and only mar-
ginally signiﬁ cant (β=0.12, p=0.037) (table 2). Furthermore, 
logistic regression analysis using COMPASS total score of >32.5 
as cut-off for the presence or absence of dysautonomia identi-
ﬁ ed ESSPRI and HAD-A as the two most important predictors 
(ﬁ gure 3).
DISCUSSION
This study aimed to determine the prevalence of autonomic 
symptoms in a large cohort of patients with PSS and to investi-
gate whether there is a relationship between autonomic symp-
toms and biological and psychosocial variables commonly found 
in PSS. We have demonstrated that symptoms of autonomic 
dysfunction are common among patients with PSS, with 55% 
fulﬁ lling the criterion of dysautonomia. Furthermore, autonomic 
dysfunction is independently associated with ESSPRI, disease 
activity (ESSDAI) and symptoms of anxiety, and possibly men-
tal fatigue.
Many case reports, case series and other studies have reported 
a link between autonomic dysfunction and PSS.6–11 13 14 28–32 
However, the sample sizes of these studies were relatively 
small, rendering estimation of the prevalence and analysis of the 
relationship between autonomic dysfunction and other clinical 
features of PSS less reliable. Analysis of the data of over 300 
patients with clinically well-characterised PSS in this study ena-
bles a more robust interrogation of the relationship between 
autonomic symptoms and other clinical features of PSS. 
Figure 3 Observed membership of the dysautonomic group as a 
function of ESSPRI and HAD-A scores in the logistic regression model. 
ESSPRI scores and HAD-A scores were signifi cant predictors of group 
membership (p<0.001 for both predictors). The solid line indicates 
the 50% predicted probability for membership of the Dysautonomic 
Group. The fi lled circles indicate those patients with COMPASS scores 
>32.5. If the model were a perfect predictor of group membership then 
all points to the right and above would be fi lled (indicating COMPASS 
scores >32.5) and all those to the left and below would be unfi lled 
(indicating COMPASS scores <32.5). COMPASS, Composite Autonomic 
Symptom Scale; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported 
Index; HAD, Hospital Anxiety and Depression Scale.
Table 2 Key statistics from stepwise multiple regression analysis 
using COMPASS total score as dependent variable to identify 
independent predictors
Model
Unstandardised 
coeffi cients
Standardised 
coeffi cients
t Signifi canceB se β
Constant 7.066 2.202  3.209 0.001
ESSPRI total 3.070 0.484 0.383 6.343 0.000
HAD-A 0.905 0.212 0.227 4.262 0.000
ESSDAI 0.589 0.225 0.128 2.620 0.009
Mental fatigue 1.223 0.584 0.125 2.094 0.037
COMPASS total=7.066+3.070 (ESSPRI total)+0.905 (HAD-A)+0.589 
(ESSDAI)+1.223 (Mental fatigue)+error
R2=0.420
COMPASS, Composite Autonomic Symptom Scale; ESSDAI, EULAR Sjögren’s Syndrome 
Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; 
HAD, Hospital Anxiety and Depression Scale.
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The multicentre design also increases the ecological validity 
of our data compared with those derived from single-centre 
studies. To our knowledge, this is the ﬁ rst large, multicentre 
study to examine the prevalence, severity and predictors of 
autonomic symptoms in PSS.
ESSPRI consists of three components: fatigue, pain and dry-
ness. Since the secretomotor domain score is among the best 
predictors of COMPASS total score,17 the correlation between 
ESSPRI and autonomic symptoms could be a consequence of 
commonalities between these instruments. Indeed, all three indi-
vidual components of ESSPRI independently predict COMPASS 
total score, although fatigue and pain are better predictors than 
dryness (online supplementary table S3). On the other hand, 
as there is no obvious commonality between the ESSDAI and 
COMPASS instruments, factors (eg, common pathogenetic 
mechanisms) other than commonalities between the instruments 
may be responsible for the correlation between ESSDAI and 
COMPASS total score. Although an association does not equate 
to causal relationship, it is tempting to speculate that autonomic 
dysfunction may play a key role in PSS pathogenesis. It is note-
worthy that antibodies against muscarinic receptor have been 
implicated in PSS pathogenesis.33–39 Therefore, investigating 
the relationship between such antibodies and autonomic dys-
function in PSS is warranted. Previous studies did not identify 
links between autonomic dysfunction and PSS disease activity. 
However, disease activity was deﬁ ned using different variables 
such as inﬂ ammatory markers, immunoglobulin or complement 
levels and white cell counts. Our study is the ﬁ rst to examine 
the relationship between autonomic symptoms and PSS disease 
activity using a validated instrument, the ESSDAI.
The positive correlation between symptoms of autonomic dys-
function and anxiety score is consistent with a previous report.9
However, the mechanistic basis for such an association remains 
unclear. Many symptoms of anxiety such as palpitations, dizzi-
ness and sweats are also symptoms of dysautonomia, and this 
may provide a possible explanation for the association between 
the COMPASS total and the anxiety scores. As the average 
anxiety score among the PSS cohort is low, it is unlikely that 
the increased COMPASS total score is a consequence of anxiety 
disorder in these patients.
Associations between autonomic symptoms and fatigue6 9
and symptoms of depression9 in patients with PSS have also 
been reported. In this study, the COMPASS total scores cor-
related signiﬁ cantly with fatigue and depression in univariate 
analyses. Although mental fatigue was independently associ-
ated with COMPASS total score, the effect was small and was 
only marginally signiﬁ cant statistically. Further study is needed 
to explore the relationship between dysautonomia and fatigue 
and depression.
The COMPASS assesses different components of autonomic 
function, grouped according to individual domains. Two other 
groups of investigators have also used this instrument to study 
patients with PSS.6 8 9 Interestingly, signiﬁ cantly higher scores in 
the secretomotor, orthostatic intolerance, pupil and focusing, and 
vasomotor domains among patients with PSS compared with 
healthy controls were observed in all four studies (including a 
follow-up study). The tendency for these autonomic symptoms 
may provide insight for understanding the mechanisms of auto-
nomic dysfunction in PSS. Furthermore, symptoms of orthos-
tatic intolerance can be effectively treated using a combination 
of non-pharmacological and pharmacological interventions. 
Thus, our observations suggest that patients with PSS should be 
assessed for symptoms of orthostatic intolerance, and managed 
appropriately in clinics.
Two groups have shown that impaired gastric emptying 
is more common in patients with PSS than in controls.40 41
However, the gastroparesis domain score was not increased 
among patients with PSS and did not correlate with the objec-
tive signs of gastroparesis,40 and clinically signiﬁ cant gastropare-
sis symptoms were rarely reported.41 Consistently, the median 
gastroparesis domain scores were zero for both patients with 
PSS and controls in this study.
There are several potential weaknesses in the design of this 
study. First, not all patients underwent the COMPASS assess-
ment, and some did not complete the questionnaire. Furthermore, 
the group completing the COMPASS questionnaire was pos-
sibly less affected by their condition, showing lower levels of 
physical fatigue and ESSPRI scores. If true, given the positive 
correlation between COMPASS total and ESSPRI scores, our 
data probably underestimate the prevalence/severity of auto-
nomic symptoms in PSS. It also raises an intriguing possibility 
that the incomplete-COMPASS and non-COMPASS groups may 
be ‘too unwell’ to complete/participate in the COMPASS assess-
ment. However, since the p values of these univariate compari-
sons were unadjusted for multiplicity, caution is needed when 
interpreting these differences between the complete-COMPASS 
group and the remaining groups of the cohort. Second, since 
the recruitment for the UKPSSR cohort is ongoing, it is possi-
ble that patients with PSS with autonomic symptoms had been 
preferentially recruited before those without dysautonomia 
or vice versa, although we consider it unlikely. Furthermore, 
the design of this study was embedded in the UKPSSR set-up, 
with analysis undertaken according to a predetermined proto-
col based on the estimated sample size needed. Therefore, we 
believe that 317 patients is a sufﬁ ciently large sample size, and, 
given the statistically highly signiﬁ cant results, we consider it 
unlikely that our conclusion would have been different even 
if we had analysed more patients from the UKPSSR cohort. 
Third, the key ﬁ ndings of this study are based on self-reported 
symptoms of dysautonomia, which may be susceptible to bias 
among the respondents. However, the COMPASS has been vali-
dated and shown to correlate well with objective autonomic 
assessments.17 42 Furthermore, the scores for the overstate-
ment domain among patients with PSS were low, suggesting 
that their autonomic symptoms are unlikely to be the result of 
psychosomatic overscoring. Finally, oral and ocular dryness are 
cardinal symptoms of PSS. Therefore, patients with PSS may 
give positive responses to two of the 10 questions in the secre-
tomotor domain of the COMPASS questionnaire regardless of 
the underlying aetiology of their symptoms, leading to poten-
tial overestimation of the severity of autonomic dysfunction in 
PSS. However, the COMPASS total score for patients with PSS 
remained signiﬁ cantly higher than that of the controls even with 
these two items scored as negative or with the entire secreto-
motor domain score removed. These observations suggest that 
factors other than potential bias in the secretomotor domain 
alone are responsible for the increased prevalence and severity 
of autonomic symptoms in PSS.
In conclusion, autonomic symptoms are common among 
patients with PSS, with a preponderance of certain symptoms 
such as orthostatic intolerance, which may be amenable to 
treatment. Symptoms of dysautonomia should therefore be 
sought when assessing patients with PSS. Moreover, autonomic 
dysfunction correlates with patient-reported outcomes and PSS 
disease activity, indicating that dysautonomia may be a key 
element of the pathological processes of PSS. Additional work 
investigating the biological and psychosocial factors in PSS-
associated dysautonomia would be worthwhile.
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